Proteotype Diagnostics is launching a new 7-year clinical study for Enlighten, its multicancer early detection (MCED) blood test, with plans to support CE-IVDR submission. The company also set additional work to optimize its platform as it ramps teams and expands presence in Portugal. Proteotype’s approach measures “protein cross sections” generated from plasma amino-acid residue biomarkers tied to cancer-specific immune activation. CEO Wesley Sukdao said the planned financing targets internal capabilities for the next regulatory and product development phase, while CSO Emma Watts described the assay workflow as a microplate-based analysis of roughly 100 microliters of plasma. A prior Nature Communications validation (cited by the company) reported an Enlighten signature that identified 78% of cancers in a study of 170 participants without incorrectly classifying healthy participants as having cancer, and also differentiated those with cancer from autoimmune and infectious states. For MCED developers, the move signals the operational shift from early biomarker proof toward multi-year, regulator-facing evidence generation—particularly in Europe where CE-IVDR requirements can be prescriptive.